July 9 Reuters Drugmaker Indivior Plc said on Tuesday it would cut about 130 jobs after lowering its profit forecast for the year due to unfavourable market conditions, adding that it would discontinue the sale of its schizophrenia drug Perseris.

The company now expected adjusted operating profit for the year to be between 285 million to 320 million, compared with its earlier forecast of 330 million to 380 million.

Due to anticipated increased payor management of the category that makes PERSERIS39; future no longer financially viable, we have determined to take the required actions to discontinue the product, CEO Mark Crossley said in a statement.

The drugmaker moved its primary listing to the United States last month to boost its growth opportunities as its proprietary treatments are U.S.centred and U.S.based investors account for nearly 50 of its overall shareholder base.

Londonlisted shares of Indivior are seen falling about 10, according to premarket indications from brokerages KEPCHEV and Stifel.

Reporting by Radhika Anilkumar in Bengaluru; Editing by Sonia Cheema and Sohini Goswami

Source Reuters